Date:	10/12/2023	
Your Name:	Rianne Oostenbrink	
Manuscript Title:	Symptomatische tumoren bij volwassenen met Neurofibromatose type 1: een diagnostische uitdaging.	
Manuscript Number (if known):	D7864	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as neede	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work					
All support for present manuscript (a funding, prov of study mate medical writing article process charges, etc.) No time limit this item.	e.g., vision erials, ing, ssing)	Click the rab key to add additional rows				
	Time frame: past 36 months					
Grants or contracts from any entity (indicated in #1 above).	if not EU-PEARL (Eu-Pearl, the innovative Medicines	EU-EARL has received funding from the Innovative Medicines Inititiatives 2 Joint Undertaking under grant agreement no 853966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA and Children's Tumor Foundation, Global Alliance for TB drugDevelopment non-profit organization, Springworks Therapeutics Inc.				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	□ None Alexion fee for consultations/advisory board	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Alexion for presentations at CTF 2023, SIOP 2022	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	□ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Rare Thyroid Therapeutics International	Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None		
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	⊠ None		
Please place an "X" next to the following statement to indicate your agreement:				